Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial

Abstract

OBJECTIVE: The study aims were 1) to describe the proportions of individuals who met criteria for melancholic, atypical, and anxious depressive subtypes, as well as subtype combinations, in a large sample of depressed outpatients, and 2) to compare subtype profiles on remission and change in depressive symptoms after acute treatment with one of three antidepressant medications. METHOD: Participants 18-65 years of age (N=1,008) who met criteria for major depressive disorder were randomly assigned to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine. Participants were classified by subtype. Those who met criteria for no subtype or multiple subtypes were classified separately, resulting in eight mutually exclusive groups. A mixed-effects model using the intent-to-treat sample compared the groups' symptom score trajectories, and logistic regression compared likelihood of remission (defined as a score ≤5 on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report). RESULTS: Thirty-nine percent of participants exhibited a pure-form subtype, 36% met criteria for more than one subtype, and 25% did not meet criteria for any subtype. All subtype groups exhibited a similar significant trajectory of symptom reduction across the trial. Likelihood of remission did not differ significantly between subtype groups, and depression subtype was not a moderator of treatment effect. CONCLUSIONS: There was substantial overlap of the three depressive subtypes, and individuals in all subtype groups responded similarly to the three antidepressants. The consistency of these findings with those of the Sequenced Treatment Alternatives to Relieve Depression trial suggests that subtypes may be of minimal value in antidepressant selection.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.14020181

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. Reimherr FW, 1984, Psychopharmacol Bull, 20, 70
  2. Sheehan DV, 1998, J Clin Psychiatry, 59, 22

Cited by

See all 175

Metadata

Authors
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J.
Affiliations
The University of Sydney (AU)
Venue
American Journal of Psychiatry
Published
2015-08-01
Volume
172
Issue
8
Pages
743-750
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2160932566
Cited by
175
References
32
Citations by year
2026: 9 · 2025: 13 · 2024: 9 · 2023: 15 · 2022: 19 · 2021: 9 · 2020: 26 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 11 · 2015: 10
FWCI
12.75
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
depression subtypes, endogenous depression, atypical depression, anxious depression, antidepressant response, escitalopram, sertraline, remission, depressive symptom trajectories, major depressive disorder, antidepressant selection
MeSH terms
Venlafaxine Hydrochloride, Adult, Antidepressive Agents, Anxiety, Cyclohexanols, Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Female, Humans, Male, Middle Aged, Outpatients, Citalopram, Treatment Outcome, Sertraline, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2015.14020181
The paper
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015). Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.14020181

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.